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CORRESPONDENCE
Letters to the Editor
Effect of Polyunsaturated
Fatty Acids on Baroreflex
Function in Heart Failure Patients
Recently in the Journal, Radaelli et al. (1) reported that 4 months
of dietary polyunsaturated fatty acid (PUFA) supplementation
enhanced baroreflex control of the circulation in heart failure
patients. Augmented cardiac-vagal baroreflex control was sug-
gested from increased bradycardiac responses to neck suction as
well as enhanced cardiac period fluctuations during spontaneous
blood pressure oscillations after PUFA supplementation. These
effects of PUFAs on the cardiac-vagal arm of the baroreflex in
heart failure patients were impressive and may be of clinical
importance.
Based on the detrimental role sympathoexcitation is believed to
exert in heart failure, a separate but equally important question is
the effect that PUFAs exert on both basal and reflexive measures of
sympathetic outflow. To address this question, Radaelli et al. (1)
used several indirect indices. First, increased low frequency heart
rate variability after PUFA supplementation was used as evidence
of reduced sympathetic activity at rest (1). Second, a greater
depressor response to neck suction, which likely is mediated via
both cardiac (vagal and sympathetic) and peripheral (sympathetic)
effects, after PUFA supplementation, was suggested to indicate
enhanced sympathoinhibitory baroreflex function (1). As pointed
out, these effects of PUFAs in heart failure patients may need to be
confirmed using more robust measures of sympathetic outflow, which
should also include responses to sympathoexcitatory stimuli (2).
To date, only a single study performed in humans has deter-
mined the effect that PUFA supplementation exerts on a direct
measure of sympathetic outflow (muscle sympathetic nerve activity
[MSNA]) (3). In that study we demonstrated that PUFA supple-
mentation had no effect on MSNA at rest (against our hypothesis
that it would reduce it). Furthermore, we observed augmented (not
depressed as we hypothesized) increases in MSNA during several
distinct sympathoexcitatory stressors (exercise and cold stress) in
young healthy adults (3). Because sympathetic outflow at rest is
increased and reflex responses to baroreflex activation/deactivation
may be impaired in heart failure patients, it is unclear whether
similar effects of PUFAs on MSNA would be observed in heart
failure patients. Accordingly, it appears that studies employing
more robust methodologies are needed to more definitively deter-
mine the effect that PUFAs exert on basal and reflexive (both
sympathoinhibitory and sympathoexcitatory during baroreflex and
nonbaroreflex stimuli) regulation of sympathetic outflow in heart
failure patients.
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Reply
We appreciate the comments by Drs. Monahan and Ray concern-
ing our suggestion that, in heart failure patients, polyunsaturated
fatty acid (PUFA) supplementation may attenuate efferent sym-
pathetic nerve overactivity (SNA) (1). We entirely agree that this
issue is of potential clinical relevance and merits direct experimen-
tal testing, as indicated in the discussion of our own study and
reinforced by Floras and Bagai in their accompanying editorial (2).
This question is made even more interesting because, as
appropriately recalled by our colleagues, they previously observed
(3) that PUFA supplementation failed to modify resting muscle
SNA in healthy individuals. Conversely, we all perfectly realize
that the two possibilities (no change in the healthy subject,
reduction in the heart failure patient) are by no means mutually
exclusive considering that regulation of autonomic ouflows is
significantly altered in cardiac systolic dysfunction, and may thus
be differentially affected by PUFA supplementation compared to
the normal condition.
While awaiting more direct evidence (cardiac norepinephrine
spillover? peroneal microneurography? metaiodobenzylguanidine
cardiac scans?), all we can do is to contemplate the most reasonable
interpretation of the indirect evidence emerging from our study,
namely that PUFA 1) increased both low- and high-frequency
powers of the RR interval; 2) potentiated cardiovascular inhibitory
control by the baroreflex; 3) fell short of significantly slowing heart
rate; and 4) markedly enhanced overall RR interval variability.
Each of the previously-cited effects points to a PUFA-related
reduction in sympathetic (and probably an enhanced vagal) nerve
activity.
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